Daridorexant (insomnia) – Addendum to Commission A22-123

Report documents

1. Addendum

   Daridorexant (insomnia) – Addendum to Commission A22-123

   published on

   12.05.2023

   Document type

   PDF document, 695 kB, EN, not accessible

   Download file : Addendum (PDF document, 695 kB, EN, not accessible)

Additional information

Project details

Project no.

A23-22

Commission

Commission awarded on 28.03.2023 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Head and nerves

Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

1. Dossier assessment

   Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V

   Project no.

   A22-123

   Last updated

   12.05.2023

   Status: Commission completed